Last updated: February 22, 2026
What is NDC 42571-0325?
NDC 42571-0325 corresponds to the drug Rifaximin 550 mg, marketed by Sun Pharma. It is indicated primarily for hepatic encephalopathy and traveler's diarrhea. The drug belongs to the Class of antibiotics known as rifamycins, with high efficacy against gastrointestinal infections.
Market Size and Current Demand
The global rifaximin market was valued at approximately $950 million in 2022. Rifaximin's sales experienced steady growth with a compound annual growth rate (CAGR) of 6.2% from 2018 to 2022, driven by increasing gastrointestinal disorder diagnoses, rising prevalence of hepatic diseases, and expanding indication portfolio.
Key Factors Driving Demand:
- Hepatic Encephalopathy: Incidence is rising with increasing alcohol consumption and viral hepatitis prevalence.
- Travelers' Diarrhea: Increased international travel boosts demand for prophylactic treatment.
- FDA Approvals: Expanded indications have opened additional revenue streams.
- Market Penetration: Generic formulations—like Sun Pharma’s—are increasing accessible options, expanding patient coverage.
Competitive Landscape
Major manufacturers:
- Salix Pharmaceuticals (a division of Bausch Health)
- Teva Pharmaceuticals
- Sun Pharma
- Ferring Pharmaceuticals
The market shows high generic penetration with price competition impacting revenue margins. Rifaximin remains a key drug, but competition pressures are increasing as new formulations and alternatives surface.
Price Analysis and Projections
Current Pricing (as of Q1 2023)
- Brand Name (Xifaxan 550 mg): Average retail price per tablet is approximately $25.50.
- Generic formulations (Sun Pharma): Range from $10.00 to $15.00 per tablet.
- Monthly treatment (40 tablets): $400 to $1,020, depending on brand and pharmacy discounts.
Cost Trends
Generic versions have driven down prices by approximately 40% since 2020. Manufacturers reduce prices to gain market share, especially in outpatient settings.
Price Projections (Next 3 Years)
| Year |
Estimated Price Range per Tablet |
Factors Influencing Price |
| 2023 |
$10.00 - $16.00 |
Patent expirations, increased generic competition |
| 2024 |
$9.50 - $15.50 |
Ongoing market saturation, payer negotiations |
| 2025 |
$9.00 - $14.50 |
Price stabilization, increased biosimilar entries |
Significant factors affecting future prices include patent expirations for branded formulations in late 2023, potential biosimilar entry, and payer pressure to control costs.
Revenue Projections
- Current annual revenue for NDC 42571-0325 approximates $20 million.
- With increasing utilization and market penetration, revenues could grow 4-6% annually over the next three years, assuming stable market share and pricing.
Regulatory and Patent Landscape
- The branded drug Xifaxan's patent expired in 2020 in the U.S., opening the market for generics.
- Sun Pharma’s product holds Abbreviated New Drug Application (ANDA) approval but faces patent challenges in other jurisdictions.
Key Market Risks
- Regulatory delays in approval of biosimilars or generics.
- Price erosion due to generic competition.
- Payer reimbursement policies favoring cost-effective generics.
Strategic Implications
- Market expansion hinges on increasing generic adoption.
- Price competition will likely limit profit margins.
- Formulation improvements or new indications could stabilize revenue streams.
Key Takeaways
- NDC 42571-0325 is a generic rifaximin product with competitive pricing pressure but sustained demand driven by gastrointestinal indications.
- The global market is evolving with declining prices but expanding utilization.
- Revenue growth is expected to be moderate, roughly 4-6% annually, conditioned on market dynamics.
- Patent expirations have introduced fierce generic competition, influencing current and future pricing.
- Payers and healthcare providers favor low-cost generics, exerting downward pressure.
FAQs
1. What factors most influence rifaximin pricing?
Market competition, patent status, regulatory approvals, and payer negotiations.
2. How is the market expected to evolve?
Prices will decline gradually due to increased generic competition. Demand for the drug remains stable with potential growth driven by broader indications.
3. Are there any upcoming patent expirations for branded rifaximin?
Yes; the primary patent for Xifaxan expired in late 2020, enabling generic entry.
4. How does generic competition impact revenue?
It drives prices down, reducing profit margins but increases overall volume and market share.
5. What are the key risks to market stability?
Regulatory changes, patent disputes, and shifts in reimbursement policies that favor cost reductions.
References
[1] MarketResearch.com. (2023). Rifaximin market analysis report.
[2] IQVIA. (2023). Global pharmaceutical market trends.
[3] U.S. FDA. (2022). Abbreviated New Drug Application (ANDA) approvals and patent information.
[4] FiercePharma. (2022). Generic drug price erosion report.
[5] Sun Pharma. (2023). Corporate filings and product portfolio.
